Poly-lactic-glycolic Acid Microspheres: A Biodegradable Marker for the Diagnosis of Aspiration in Hamsters

Springer, Chaim; Benita, Simon; Sherman, Yoav; Gursoy, Neslihan; Gilhar, Dalia; Avital, Avraham

doi:10.1203/01.pdr.0000176910.62067.a0

Cited by 11 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They noticed an acute inflammatory response on the instillation day of PLGA particles, demonstrated by an increase in neutrophils in whole-lung lavage and lung parenchyma of hamsters, that disappeared thereafter. 124 V. F. Fiore et al compared the inflammatory response of polyketal (PK3) with PLGA microparticles after intratracheal injection in mice in order to investigate their potential use as drug delivery vehicles for interstitial lung diseases (ILD). Their results showed that PLGA microparticles induced a significant macrophage infiltration starting at day 4 and continuing through day 7 and a transient lymphocyte infiltration at day 4, while PK3 particles did not exhibit any airway inflammation.…”

Section: Organic Nanoparticles In Immunological Applicationsmentioning

confidence: 99%

Biomedical nanomaterials for immunological applications: ongoing research and clinical trials

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Organic Nanoparticles In Immunological Applicationsmentioning

confidence: 99%

Biomedical nanomaterials for immunological applications: ongoing research and clinical trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…178 Aspiration of PLGA microspheres was found to be safe over 90 days of monitoring and caused no histological abnormalities in internal organs of hamsters. 179 In addition, it has been extensively used as an anticancer drug carrier. 180 Since the contact with mucus and underlying epithelia is mediated by the vehicle surface, the selected examples of polyester-based particles modified with biomimetic ligands for transepithelial drug delivery are presented within this chapter and summarized in Table 3.…”

Section: Particulate Functional Polymers For Transepithelial Drug Del...mentioning

confidence: 99%

Particulate transepithelial drug carriers: barriers and functional polymers

et al. 2012

View full text Add to dashboard Cite

This review may serve as a compilation of helpful guidelines for design, synthesis, formulation, and in vitro, ex vivo as well as in vivo evaluation of particulate drug delivery systems that cross epithelial barriers. It provides both chemist and biologist with a comprehensive overview of complex anatomorphological features encountered by intranasally, pulmonary and orally administered particles. In addition, the materials (structures, modifications, formulations, and activity) used in transepithelial delivery are discussed. It covers the biological as well as physicochemical aspects crucial for the successful development of particulate drug carriers and methods for their application.

show abstract

“…Previous studies report that an intratracheal dose of 1 mg of PLGA microparticles in a rodent model results in a large recruitment of white blood cells to the lungs, indicative of an inflammatory response [12]. Within 24 hours of injection, PLGA treated lungs contained ~10 5 macrophages/mL of bronchoalveolar lavage (BAL) fluid, whereas controls contained only 10 4 macrophages/mL BAL fluid.…”

Section: Introductionmentioning

confidence: 99%

Polyketal microparticles for therapeutic delivery to the lung

et al. 2010

View full text Add to dashboard Cite

Inflammation in the setting of interstitial lung disease (ILD) occurs in the distal alveolar spaces of the lung, which presents significant challenges for therapeutic delivery. The development of aerosolizable microparticles from non-immunogenic polymers is needed to enable the clinical translation of numerous experimental therapeutics that require localization to the deep lung and repeated delivery for optimal efficacy. Polyketals (PK), a family of polymers, have several unique properties that make them ideal for lung delivery, specifically their hydrolysis into non-acidic, membrane-permeable compounds and their capacity to form microparticles with the aerodynamic properties needed for aerosolization. In this study, we tested the lung biocompatibility of microparticles created from a polyketal polymer, termed PK3, following intratracheal instillation in comparison to commonly used PLGA microparticles. We furthermore tested the initial efficacy of PK3 microparticles to encapsulate and effectively deliver active superoxide dismutase (SOD), a free radical scavenging enzyme, in a model of lung fibrosis. Our findings indicate that PK3 microparticles display no detectable level of alveolar or airway inflammation, whereas PLGA induced a small inflammatory response. Furthermore, SOD loaded into PK3 microparticles maintained its activity upon release and, when delivered via PK3 microparticles, inhibited the extent of lung fibrosis.

show abstract

Poly-lactic-glycolic Acid Microspheres: A Biodegradable Marker for the Diagnosis of Aspiration in Hamsters

Cited by 11 publications

References 25 publications

Biomedical nanomaterials for immunological applications: ongoing research and clinical trials

Biomedical nanomaterials for immunological applications: ongoing research and clinical trials

Particulate transepithelial drug carriers: barriers and functional polymers

Polyketal microparticles for therapeutic delivery to the lung

Contact Info

Product

Resources

About